Ribomic, Inc.

As of March 31, 2026, Ribomic, Inc. carries a market capitalization of 4.78B, placing it among publicly traded companies globally. Its enterprise value stands at 1.95B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Ribomic, Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, Ribomic, Inc. has 54.31M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Ribomic, Inc. maintains a current ratio of 21.68, meaning it holds 21.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Ribomic, Inc.'s stock has declined approximately 31.58% over the past 52 weeks. The 50-day moving average sits at 78.44, while the 200-day moving average is 79.38.

These figures are as of March 31, 2026. Total book value stands at 2.84B, with working capital of 2.79B providing operational flexibility.